Boezeman A J, Kayser A M, Siemelink R J
Militair Hospitaal Dr A. Mathijsen Utrecht, The Netherlands.
J Antimicrob Chemother. 1988 Jul;22 Suppl B:165-70. doi: 10.1093/jac/22.supplement_b.165.
In an open randomized comparative study, the clinical and bacteriological efficacy and safety of spiramycin were compared with those of doxycycline in patients with acute sinusitis. Spiramycin was given at a dose of 1 g bd for 10 days and doxycycline at 200 mg once a day on day 1 and 100 mg once a day from day 2 to day 10. Clinical and bacteriological evaluations of efficacy were carried out at the end of therapy. In case of clinical cure, a last follow-up visit was made 15 days after the end of therapy. Adverse effects were recorded. To date 12 assessable patients have been treated with spiramycin and 15 with doxycycline. In the spiramycin group, nine patients were clinically cured at the end of therapy (with no relapse at the last follow-up visit). In the doxycycline group, nine patients were clinically cured at the end of therapy (with no relapse at the last follow-up visit). The data so far available from this study suggest that spiramycin presents an alternative to doxycycline in the treatment of acute sinusitis.
在一项开放性随机对照研究中,比较了螺旋霉素与强力霉素治疗急性鼻窦炎患者的临床、细菌学疗效及安全性。螺旋霉素剂量为每日2次,每次1g,连用10天;强力霉素第1天剂量为200mg,每日1次,第2天至第10天剂量为100mg,每日1次。治疗结束时进行临床和细菌学疗效评估。临床治愈者,在治疗结束后15天进行最后一次随访。记录不良反应。迄今为止,12例可评估患者接受了螺旋霉素治疗,15例接受了强力霉素治疗。螺旋霉素组中,9例患者治疗结束时临床治愈(最后一次随访无复发)。强力霉素组中,9例患者治疗结束时临床治愈(最后一次随访无复发)。该研究目前可得的数据表明,在急性鼻窦炎治疗中,螺旋霉素可作为强力霉素的替代药物。